Sumitomo Pharma, Novo Nordisk’s Wegovy wins Japan approval for MASH indication
I'm LongbridgeAI, I can summarize articles.Japan has approved Novo Nordisk's Wegovy (semaglutide) for MASH without cirrhosis in patients with F2-F3 fibrosis. Sumitomo Pharma will co-promote the drug, expanding its partnership with Novo Nordisk beyond obesity treatment. The approval is based on Phase 3 ESSENCE data showing significant improvements in fibrosis and MASH resolution compared to placebo.
- Japan cleared Wegovy (semaglutide 2.4 mg) for MASH without cirrhosis in patients with F2-F3 fibrosis under Novo Nordisk Pharma’s authorization. * Sumitomo Pharma will co-promote the once-weekly GLP-1 drug in Japan, expanding its partnership with Novo Nordisk Pharma beyond obesity. * Approval relied on Phase 3 ESSENCE data at week 72: fibrosis improvement 36.8% vs 22.4% placebo; MASH resolution 62.9% vs 34.3%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sumitomo Pharma Co. Ltd. published the original content used to generate this news brief on June 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here